Browsing Faculty of Natural Sciences by Subject "Tuberculosis"
Now showing items 1-20 of 25
-
2-Arylnaphthoquinone analogues: Potential anti-TB and pro-apoptotic agents
(Green, I. R. et al. (2011). 2-Arylnaphthoquinone analogues: Potential anti-TB and pro-apoptotic agents. ARKIVOC, (x), 192-212. https://doi.org/10.3998/ark.5550190.0012.a16, 2011)A useful library of substituted 2-arylnaphthoquinones prepared by reaction between the corresponding bromonaphthoquinones and arylboronic acids via Suzuki-Miyaura protocols has been established. Conversion of some of the ... -
Acute pharmacokinetics of first line anti-tuberculosis drugs in patients with Pulmonary Tuberculosis and in patients with Pulmonary Tuberculosis co-infected with HIV
(David Publishing, 2011)The aim of this study was to compare the pharmacokinetics of antituberculosis drugs in patients with pulmonary tuberculosis (PTB) and in patients with PTB and HIV during the first 24 h of treatment. Designed as a ... -
Acyldepsipeptide analogues: A future generation antibiotics for Tuberculosis treatment
(MDPI, 2022)Acyldepsipeptides (ADEPs) are a new class of emerging antimicrobial peptides (AMPs), which are currently explored for treatment of pathogenic infections, including tuberculosis (TB). These cyclic hydrophobic peptides ... -
Amount of cycloserine emanating from terizidone metabolism and relationship with hepatic function in patients with drug resistant tuberculosis
(Springer, 2019)The dosing of cycloserine and terizidone is the same, as both drugs are considered equivalent or used interchangeably. Nevertheless, it is not certain from the literature that these drugs are interchangeable. Therefore, the ... -
Antimycobacterial activity and molecular docking of methanolic extracts and compounds of marine fungi from Saldanha and False Bays, South Africa
(Elsevier, 2022)The number and diversity of drugs in the tuberculosis (TB) drug development process has increased over the years, yet the attrition rate remains very high, signaling the need for continued research in drug discovery. In ... -
Associations between human leukocyte antigen class I variants and the Mycobacterium tuberculosis subtypes causing disease
(Oxford University Press, 2013)BACKGROUND. The development of active tuberculosis disease has been shown to be multifactorial. Interactions between host and bacterial genotype may influence disease outcome, with some studies indicating the adaptation ... -
Capacity building for whole genome sequencing of Mycobacterium tuberculosis and bioinformatics in high TB burden countries
(Oxford University Press, 2020)Background Whole-genome sequencing (WGS) is increasingly used for Mycobacterium tuberculosis (Mtb) research. Countries with the highest tuberculosis (TB) burden face important challenges to integrate WGS into surveillance ... -
Challenges of biobanking in South Africa to facilitate indigenous research in an environment burdened with human immunodeficiency virus, tuberculosis, and emerging non-communicable diseases
(Mary Ann Liebert, Inc., 2013)The high burden of infectious diseases and the growing problem of noncommunicable and metabolic disease syndromes in South Africa (SA) forces a more focused research approach to facilitate cutting-edge scientific growth ... -
The combat-tb workbench: Making powerful Mycobacterium tuberculosis bioinformatics accessible
(American Society for Microbiology, 2022)Whole-genome sequencing (WGS) is a powerful method for detecting drug resistance, genetic diversity, and transmission dynamics of Mycobacterium tuberculosis. Implementation of WGS in public health microbiology laboratories ... -
Determination of kanamycin plasma levels using LC-MS and its pharmacokinetics in patients with multidrug-resistant tuberculosis with and without HIV-infection
(OMICS, 2015)The objectives of the study were: (1) to determine kanamycin plasma concentrations using liquid chromatography coupled with mass spectrometry (LC-MS), (2) to investigate kanamycin pharmacokinetics (PK) in patients with ... -
Health trends, inequalities and opportunities in South Africa’s provinces, 1990–2019: Findings from the Global burden of disease 2019 Study
(BMJ Publishing Group, 2022)Over the last 30 years, South Africa has experienced four ’colliding epidemics’ of HIV and tuberculosis, chronic illness and mental health, injury and violence, and maternal, neonatal, and child mortality, which have ... -
Insights into innovative therapeutics for drug-resistant tuberculosis: Host-directed therapy and autophagy inducing modified nanoparticles
(Elsevier, 2022)Tuberculosis (TB) remains one of the deadliest communicable dis- eases caused by Mycobacterium tuberculosis (Mtb) since its discovery in the 1880s (Cambau and Drancourt, 2014; Singh et al., 2020). Over 1 billion mortalities ... -
The macrophage response to mycobacterium tuberculosis and opportunities for autophagy inducing nanomedicines for Tuberculosis therapy
(Frontiers Media S.A., 2021)The major causative agent of tuberculosis (TB), i.e., Mycobacterium tuberculosis (Mtb), has developed mechanisms to evade host defense responses and persist within host cells for prolonged periods of time. Mtb is also ... -
A model of population dynamics of TB in a prison system and application to South Africa
(BioMed Central, 2017)BACKGROUND: Tuberculosis (TB) continues to spread in South African prisons in particular, as prisons are over-capacitated and have poor ventilation. The awaiting trial detainees are not screened on admission and are at ... -
Molecular evolution of key receptor genes in primates and non-human primates
(Science Publishing Group, 2014)African primates remain an unexplored source of information required to complete the origin and evolution of many human pathogens. Current studies have shown the importance of several receptor human genes implicated in ... -
Nanomedicines for infectious diseases
(Springer Nature, 2019)Infectious diseases continue to pose a significant threat to global health. Over 200 infectious diseases are currently known to man. Fortunately, only a handful are responsible for significant morbidity and mortality. ... -
Planned, ongoing and completed tuberculosis treatment trials in Brazil, Russia, India, China and South Africa: A 2019 cross-sectional descriptive analysis
(BMJ Publishing Group, 2022)Tuberculosis (TB) remains a deadly challenge globally and Brazil, Russia, India, China and South Africa (BRICS) are among the countries with the highest TB burden. The objective of this study is to identify and ... -
Recent advances in the detection of interferon‑gamma as a TB biomarker
(Springer, 2021)Tuberculosis (TB) is one of the main infectious diseases worldwide and accounts for many deaths. It is caused by Mycobacterium tuberculosis usually afecting the lungs of patients. Early diagnosis and treatment are essential ... -
Repurposing based identification of novel inhibitors against mmps5-mmpl5 efflux pump of Mycobacterium smegmatis: A combined in silico and in vitro study
(MDPI, 2022)In the current era of a pandemic, infections of COVID-19 and Tuberculosis (TB) enhance the detrimental effects of both diseases in suffering individuals. The resistance mechanisms evolving in Mycobacterium tuberculosis ... -
Steady‐state population pharmacokinetics of terizidone and itsmetabolite cycloserine in patients with drug‐resistanttuberculosis
(Wiley, 2019)Despite terizidone being part of the second‐line recommended drugs fortreatment of drug‐resistant tuberculosis (DR‐TB), information on its pharmacokineticsis scarce. The aim of this study was to describe the steady‐state ...